1887

Abstract

The polivoirus/human immunodeficiency virus (HIV) chimera S1/env/3 presents the sequence DRPEGIEEE-GGERDRDRS, a known glycoprotein gp41 neutralizing domain (residues 735 to 752) of HIV IIIB in an antigenic site of the Sabin type 1 strain of poliovirus. Of 10 monoclonal antibodies raised against the sequence as presented in S1/env/3, eight were shown to neutralize HIV IIIB whereas all 10 neutralized S1/env/3, suggesting that the presentation of the sequence is comparable between HIV and the poliovirus/HIV chimera. The monoclonal antibodies were characterized by the selection of escape mutants from S1/env/3 and by Pepscan analysis. The two methods gave similar results, identifying two epitopes involving amino acids corresponding to residues 740 to 743, and to residues 745 to 750 of gp41. Mutations selected in the chimera with S1/env/3-specific MAbs are identical or similar to changes occurring in natural isolates of HIV-1. This finding suggests that the epitope may be significant in the neutralization of HIV .

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-12-2603
1993-12-01
2024-04-25
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/12/JV0740122603.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-12-2603&mimeType=html&fmt=ahah

References

  1. Altmeyer R., Murdin A. D., Harber J. J., Wimmer E. 1991; Construction and characterization of a poliovirus/rhinovirus antigenic hybrid. Virology 184:636–644
    [Google Scholar]
  2. Broliden P. A., Von Gegerfelt A., Clapham P., Rosen J., Fenyo E. M., Wahren B., Broliden K. 1992; Identification of human neutralization-inducing regions of the human immunodeficiency virus type-1 envelope glycoproteins. Proceedings of the National Academy of Sciences, U,. S,. A 89:461–465
    [Google Scholar]
  3. Burke K. L., Dunn G., Ferguson M., Minor P. D., Almond J. W. 1988; Antigen chimeras of poliovirus as potential new vaccines. Nature, London 332:81–82
    [Google Scholar]
  4. Davis D., Chaudhri B., Stephens D. M., Carne C. A., Willers C., Lachmann P. J. 1990; The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host’s previous exposure to similar epitopes on unrelated antigens. Journal of General Virology 71:1975–1983
    [Google Scholar]
  5. D’Souza M. P., Durda P., Hanson C. V., Milman G., Corcoran T. Collaborating Investigators 1991; Evaluation of monoclonal antibodies to HIV-1 by neutralisation and serological assays: an international collaboration. AIDS 5:1061–1070
    [Google Scholar]
  6. Evans D. J., McKeating J., Meredith J. M., Burke K. L., Katrak K., John A., Ferguson M., Minor P. D., Weiss R. A., Almond J. W. 1989; An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralising antibodies. Nature, London 339:385–388
    [Google Scholar]
  7. Gelderblom H. R., Ozel M., Pauli G. 1989; Morphogenesis and morphology of HIV: structure-function relations. Archives of Virology 106:1–13
    [Google Scholar]
  8. Geysen H. M., Meloen R. H., Barteling S. J. 1984; Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid. Proceedings of the National Academy of Sciences, U,. S,. A 81:3998–4002
    [Google Scholar]
  9. Hahn B., Manzari V., Colombini S., Franchini G., Gallo R. C., Wong-Staal F. 1983; Common site of integration of HTLV in cells of three patients with mature T-cell leukaemia-lymphoma. Nature, London 303:235–256
    [Google Scholar]
  10. Kennedy R. C., Henkel R. D., Puletti D., Allan J. S., Lee T. H., Essex M., Dreesman G. R. 1986; Antiserum to a synthetic peptide recognises HTLV-III envelope glycoprotein. Science 231:1556–1559
    [Google Scholar]
  11. Kieny M. P., Rautmann G., Schmitt D., Dott K., Wain-Hobson S., Alizon M., Girard M., Chamaret S., Laurent A., Montagnier L., Lecocq J. P. 1986; AIDS virus env protein expressed from a recombinant vaccinia virus. Bio/Technology 4:790–795
    [Google Scholar]
  12. Kitson J. D., Burke K. L., Pullen L. A., Belsham G. J., Almond J. W. 1991; Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot and mouth disease virus (FMDV) induce neutralising antibodies against FMDV in guinea pigs. Journal of Virology 65:3068–3075
    [Google Scholar]
  13. LaRosa G. J., Davide J. P., Weinhold K., Waterbury J. A., Profy A. T., Lewis J. A., Langlois A. J., Dreesman G. R., Boswell R. N., Shadduck P. 1990; Conserved sequences and structural elements in HIV-1 principal neutralising determinant. Science 249:932–935 [published erratum Science (1991). 251, 811]
    [Google Scholar]
  14. Macadam A. J., Arnold C., Howlett J., John A., Marsden S., Taffs F., Reeve P., Hamada N., Wareham K., Almond J., Cammack N., Minor P. D. 1989; Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of polioviruses in vaccinees. Virology 172:408–114
    [Google Scholar]
  15. Minor P. D., Schild G. C., Bootman J., Evans D. M. A., Ferguson M., Reeve P., Spitz M., Stanway G., Cann A. J., Hauptmann R., Clarke L. D., Mountford R. C., Almond J. W. 1983; Location and primary structure of a major antigenic site for poliovirus neutralization. Nature, London 301:674–679
    [Google Scholar]
  16. Minor P. D., Ferguson M., Evans D. M. A., Almond J. W., Icenogle J. P. 1986; Antigenic structure of polioviruses of serotypes 1, 2 and 3. Journal of General Virology 67:1283–1291
    [Google Scholar]
  17. Minor P. D., Ferguson M., Phillips A., Magrath D. I., Huovil-ainen A., Hovi T. 1987; Conservation in vivo of protease cleavage sites in antigenic sites of poliovirus. Journal of General Virology 68:1857–1865
    [Google Scholar]
  18. Page M., Mills K. H. G., Schild G. C., Ling C., Patel V., McKnight A., Barnard A. L., Dilger P., Thorpe R. 1991; Studies on the immunogenicity of Chinese hamster ovary cell-derived recombinant gp120 (HIV-1 IIIB). Vaccine 9:47–52
    [Google Scholar]
  19. Pinter A., Honnen W. J., Tilley S. A., Bona C., Zaghouani H., Gorny M. K., Zolla-Pazner S. 1989; Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1. Journal of Virology 63:2674–2679
    [Google Scholar]
  20. Popovic M., Sarngadharan M. G., Read E., Gallo R. C. 1984; Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497–500
    [Google Scholar]
  21. Rose C. S. P., Evans D. 1991; Poliovirus antigen chimeras. Trends in Biotechnology 9:415–421
    [Google Scholar]
  22. Sanger F., Nicklen S., Coulson A. R. 1977; DNA sequencing with chain-terminating inhibitors. Proceedings of the National Academy of Sciences, U,. S,. A 74:5463–5467
    [Google Scholar]
  23. Schneider J., Kaaden O., Copeland T. D., Oroszlan S., Hunsmann G. 1986; Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. Journal of General Virology 67:2533–2538
    [Google Scholar]
  24. Vella C., Minor P. D., Weller I. V. D., Jenkins O., Evans D., Almond J. W. 1991; Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS 5:425–130
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-12-2603
Loading
/content/journal/jgv/10.1099/0022-1317-74-12-2603
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error